Abstract:Objective To estimate the immune memory at 12 years after hepatitis B vaccination and its risk factors among adults. Methods The study was conducted in 20 villages of Qudi town in Jiyang county, Shandong province, China in 2003. Hepatitis B surface antigen (HBsAg), antibody against HBsAg (anti?HBs) and antibody against hepatitis B core antigen (anti?HBc) were tested for all healthy residents aged 15-40 years in these villages. Those who had no history of hepatitis B vaccination and were negative for all three indicators were divided into two groups randomly. Hepatitis B vaccine (HepB) was administrated to them on 0?6 month schedule or 0?1?6 month schedule respectively. Blood samples were obtained at one month after the last dose for each receipt and were quantitatively detected for anti?HBs. Finally a total of 629 participants completed HepB vaccination and anti?HBs testing, including 288 of two?dose group and 341 of three?dose group respectively. In 2015, an additional dose of HepB (challenge dose) was administrated to those who were negative for anti?HBs at follow?up (anti?HBs<10 mIU/ml) to evaluate the immune memory. A total of 93 blood samples, including 50 of two?dose group and 43 of three?dose group respectively, were drawn at 14 days after the challenge dose and anti?HBs was quantitatively detected. The anti?HBs geometric mean concentrations (GMCs) after the challenge dose were compared between the two groups. Multivariate linear regression model was built to find the independent risk factors associated with immune memory response (anti?HBs GMC after the challenge dose). Results The challenge dose of HepB and post?challenge anti?HBs detection were completed among 93 participants. Totally 92 (98.92%, 92/93) participants were found holding immune memory (anti?HBs after the challenge dose was≥10 mIU/ml). The immune memory positive rates were 100% (50/50) and 97.67% (42/43) in the two?dose group and three?dose group respectively and the corresponding anti?HBs GMC after challenge dose were 2 684.30 (95%CI :1 721.71-4 185.08) mIU/ml and 3 527.48 (95%CI:2 145.15-5 800.58) mIU/ml (P=0.410). The anti?HBs GMC after the challenge dose were 1 908.33 (95%CI: 1 190.01-3 060.27) mIU/ml, 4 004.20 (95%CI:2 257.90-7 101.12) mIU/ml and 8 682.16 (95%CI: 5 813.94-12 965.36) mIU/ml among the participants whose anti?HBs titer was<4, 4-6 and 7-9 mIU/ml at follow?up, respectively (P=0.002). There was no correlation between immune schedule and anti?HBs GMC after the challenge dose; β (95%CI) was-0.07 (-0.34-0.20), P=0.601. Conclusion The immune memory after primary hepatitis B vaccination lasted for at least 12 years among adults. The immune memory response was independently associated with ant?HBs titer at follow?up, but might be similar between 0?6 month schedule and 0?1?6 month schedule.

Long-term efficacy and immunological memory of plasma-derived hepatitis B vaccine 11 years after initial inoculation

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

Efficacy of plasma-derived hepatitis B vaccine produced by China 9 years after initial injection

Antibody Levels and Immune Memory 23 Years after Primary Plasma-Derived Hepatitis B Vaccination: Results of a Randomized Placebo-Controlled Trial Cohort from China Where Endemicity is High

Longitudinal Mapping of Hepatitis B Vaccine-Induced B-cell Linear Epitopes in Healthy Individuals

[Effect of Plasma-Derived Hepatitis B Vaccine 23(rd) Year after a Full Course of Vaccination in Healthy Young Children].

Comparison of Long-Term Immunogenicity (23 Y) of 10 Μg and 20 Μg Doses of Hepatitis B Vaccine in Healthy Children

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

[Long-term efficacy and persistence of Chinese infants after receiving only active plasma-derived hepatitis B vaccine]

Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China

The long-term efficacy of recombinant hepatitis B vaccines for children

Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose

Persistence of immune memory and its related factors at 12 years after hepatitis B vaccination among adults

SIX-YEAR EFFICACY OF HEPATITIS B REVACCINATION: ADOUBLE-BLIND, PLACEBO-CONTROLLED AND RANDOMIZED FIELD TRIAL

Long-Term Efficacy And Immune Memory Of Neonatal Recombinant Hepatitis B Vaccination In Adolescents Aged 13-14 Years

Modeling Long-Term Persistence after 8 Years of Hepatitis B Booster Vaccination in 5- to 15-Year-old Children

The One Year Effects of Three Doses of Hepatitis B Vaccine As a Booster in Anti-Hbs-negative Children 11–15 Years after Primary Immunization; China, 2009–2011

Long-term Evaluation of Immune Efficacy among Newborns 16 Years after HBV Vaccination

Long-term Persistence of Anti-Hbs after Hepatitis B Vaccination among Isolated Anti-Hbc Positive Adults in China: 8-Years Results

[Long-Term Efficacy Study of Hepatitis B Vaccination in Newborns--results of 11 Years' Follow-Up].

Persistence of Immune Memory among Adults with Normal and High Antibody Response to Primary Hepatitis B Vaccination: Results from a Five-Year Follow-Up Study in China